Supernus Pharmaceuticals, Inc. (SUPN): Price and Financial Metrics

SUPN POWR Grades

• SUPN scores best on the Value dimension, with a Value rank ahead of 96.96% of US stocks.
• SUPN's strongest trending metric is Quality; it's been moving up over the last 177 days.
• SUPN's current lowest rank is in the Sentiment metric (where it is better than 10.4% of US stocks).

SUPN Stock Summary

• With a one year PEG ratio of 1,190.88, SUPERNUS PHARMACEUTICALS INC is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 97.88% of US stocks.
• With a year-over-year growth in debt of -92.26%, SUPERNUS PHARMACEUTICALS INC's debt growth rate surpasses only 1.53% of about US stocks.
• SUPERNUS PHARMACEUTICALS INC's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is 27.21%, greater than the shareholder yield of 92.57% of stocks in our set.
• Stocks with similar financial metrics, market capitalization, and price volatility to SUPERNUS PHARMACEUTICALS INC are GDRX, CTS, AUID, SPSC, and MITK.
• Visit SUPN's SEC page to see the company's official filings. To visit the company's web site, go to www.supernus.com.

SUPN Valuation Summary

• In comparison to the median Healthcare stock, SUPN's EV/EBIT ratio is 322.34% higher, now standing at 41.6.
• SUPN's price/sales ratio has moved down 164.5 over the prior 140 months.

Below are key valuation metrics over time for SUPN.

SUPN Growth Metrics

Its 2 year cash and equivalents growth rate is now at -48.75%.
• Its 4 year revenue growth rate is now at 76.13%.
• Its 3 year net cashflow from operations growth rate is now at -29.38%.

SUPN's revenue has moved up $266,205,000 over the prior 33 months.

The table below shows SUPN's growth in key financial areas (numbers in millions of US dollars).

Date	Revenue	Operating Cash Flow	Net Income to Common Stock
2022-09-30	658.96	138.025	37.672
2022-06-30	630.071	120.074	57.485
2022-03-31	601.349	95.229	73.346
2021-12-31	579.775	127.127	53.424
2021-09-30	564.282	110.297	81.75
2021-06-30	570.953	120.006	100.185

SUPN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.

• SUPN has a Quality Grade of B, ranking ahead of 91.1% of graded US stocks.
• SUPN's asset turnover comes in at 0.375 -- ranking 128th of 682 Pharmaceutical Products stocks.
• RETA, INVA, and PTCT are the stocks whose asset turnover ratios are most correlated with SUPN.

The table below shows SUPN's key quality metrics over time.